Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes

Drug Metabolism and Disposition

Volumn 39, Issue 1, 2011, Pages 54-60

  Koga, Toshihisa ^a   Fujiwara, Ryoichi ^a   Nakajima, Miki ^a   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL GLUCURONIDE; BORNEOL; DICLOFENAC; GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A4; IBUPROFEN; KETOPROFEN; NAPROXEN; UNCLASSIFIED DRUG;

ARTICLE; COMET ASSAY; CONTROLLED STUDY; DETOXIFICATION; DNA DAMAGE; DRUG CYTOTOXICITY; EMBRYO CELL; ENZYME ACTIVITY; GENOTOXICITY; GLUCURONIDATION; HUMAN; HUMAN CELL; KIDNEY CELL; LIVER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIMED DRUG RELEASE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BORNANES; COMET ASSAY; DNA DAMAGE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HEK293 CELLS; HEPATOCYTES; HUMANS; KIDNEY;

EID: 78650743790     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.035600     Document Type: Article

References (35)

1. Ashby J, Brady A, Elcombe CR, Elliot BM, Ishamael J, Odum J, Tugwood JD, Kettle S, and Purchase IFH (1994) Mechanistically-based human hazard assessment of peroxisome proliferator- induced hepatocarcinogenesis. Hum Exp Toxicol 13 (Suppl 2):S1-S117. (Pubitemid 24356585)
2. Bailey MJ and Dickinson RG (2003) Acyl glucuronide reactivity in perspective: biological consequences. Chem Biol Interact 145:117-137.
3. Banks AT, Zimmerman HJ, Ishak KG, and Harter JG (1995) Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 22:820-827.
4. Boelsterli UA (2003) Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 192:307-322.
5. Boelsterli UA, Zimmerman HJ, and Kretz-Rommel A (1995) Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: molecular mechanisms and pathology. Crit Rev Toxicol 25:207-235.
6. Brambilla G and Martelli A (2009) Genotoxicity and carcinogenicity studies of analgesics, anti-inflammatory drugs and antipyretics. Pharmacol Res 60:1-17.
7. Castillo M and Smith PC (1995) Disposition and reactivity of ibuprofen and ibufenac acyl glucuronides in vivo in the rhesus monkey and in vitro with human serum albumin. Drug Metab Dispos 23:566-572.
8. Cuthbert MF (1974) Adverse reactions to non-steroidal antirheumatic drugs. Curr Med Res Opin 2:600-610.
9. Foster RT, Jamali F, Russell AS, and Alballa SR (1988) Pharmacokinetics of ketoprofen enantiomers in young and elderly arthritic patients following single and multiple doses. J Pharm Sci 77:191-195.
10. Fujiwara R, Nakajima M, Yamanaka H, Nakamura A, Katoh M, Ikushiro S, Sakaki T, and Yokoi T (2007a) Effects of coexpression of UGT1A9 on enzymatic activities of human UGT1A isoforms. Drug Metab Dispos 35:747-757.
11. Fujiwara R, Nakajima M, Yamanaka H, Katoh M, and Yokoi T (2007b) Interactions between human UGT1A1, UGT1A4, and UGT1A6 affect their enzymatic activities. Drug Metab Dispos 35:1781-1787.
12. Hagmann W, Nies AT, König J, Frey M, Zentgraf H, and Keppler D (1999) Purification of the human apical conjugate export pump MRP2 reconstitution and functional characterization as substrate-stimulated ATPase. Eur J Biochem 265:281-289.
13. Hirano M, Maeda K, Shitara Y, and Sugiyama Y (2004) Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311:139-146.
14. Kohn KW (1991) Principles and practice of DNA filter elution. Pharmacol Ther 49:55-77.
15. Kubota T, Lewis BC, Elliot DJ, Mackenzie PI, and Miners JO (2007) Critical roles of residues 36 and 40 in the phenol and tertiary amine aglycone substrate selectivities of UDPglucuronosyltransferases 1A3 and 1A4. Mol Pharmacol 72:1054-1062.
16. Kumar S, Samuel K, Subramanian R, Braun MP, Stearns RA, Chiu SH, Evans DC, and Baillie TA (2002) Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide. J Pharmacol Exp Ther 303:969-978.
17. Lagas JS, Sparidans RW, Wagenaar E, Beijnen JH, and Schinkel AH (2010) Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters. Mol Pharmacol 77:687-694.
18. Nakajima M, Koga T, Sakai H, Yamanaka H, Fujiwara R, and Yokoi T (2010) N-Glycosylation plays a role in protein folding of human UGT1A9. Biochem Pharmacol 79:1165-1172.
19. Nishiyama T, Izawa T, Usami M, Ohnuma T, Ogura K, and Hiratsuka A (2010) Cooperation of NAD(P)H:quinone oxidoreductase 1 and UDP-glucuronosyltransferases reduces menadione cytotoxicity in HEK293 cells. Biochem Biophys Res Commun 394:459-463.
20. Pirmohamed M, Madden S, and Park BK (1996) Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism. Clin Pharmacokinet 31:215-230.
21. Riedmaier S, Klein K, Hofmann U, Keskitalo JE, Neuvonen PJ, Schwab M, Niemi M, and Zanger UM (2010) UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther 87:65-73.
22. Riley TR 3rd and Smith JP (1998) Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series. Am J Gastroenterol 93:1563-1565.
23. Ritter JK (2000) Roles of glucuronidation and UDP- glucuronosyltransferases in xenobiotic bioactivation reactions. Chem Biol Interact 129:171-193.
24. Sakaguchi K, Green M, Stock N, Reger TS, Zunic J, and King C (2004) Glucuronidation of carboxylic acid containing compounds by UDP- glucuronosyltransferase isoforms. Arch Biochem Biophys 424:219-225.
25. Sallustio BC, Degraaf YC, Weekley JS, and Burcham PC (2006) Bioactivation of carboxylic acid compounds by UDP-glucuronosyltransferases to DNA-damaging intermediates: role of glycoxidation and oxidative stress in genotoxicity. Chem Res Toxicol 19:683-691.
26. Sallustio BC, Harkin LA, Mann MC, Krivickas SJ, and Burcham PC (1997) Genotoxicity of acyl glucuronide metabolites formed from clofibric acid and gemfibrozil: a novel role for phase- II-mediated bioactivation in the hepatocarcinogenicity of the parent aglycones? Toxicol Appl Pharmacol 147:459-464.
27. Seitz S and Boelsterli UA (1998) Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats. Gastroenterology 115:1476-1482.
28. Shipkova M, Armstrong VW, Oellerich M, and Wieland E (2003) Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 25:1-16.
29. Singh NP, McCoy MT, Tice RR, and Schneider EL (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175:184-191.
30. Southwood HT, DeGraaf YC, Mackenzie PI, Miners JO, Burcham PC, and Sallustio BC (2007) Carboxylic acid drug-induced DNA nicking in HEK293 cells expressing human UDPglucuronosyltransferases: role of acyl glucuronide metabolites and glycation pathways. Chem Res Toxicol 20:1520-1527.
31. Tang W, Stearns RA, Wang RW, Chiu SH, and Baillie TA (1999) Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. Chem Res Toxicol 12:192-199.
32. Vree TB, Van Den Biggelaar-Martea M, Verwey-Van Wissen CP, Vree ML, and Guelen PJ (1993) The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. Br J Clin Pharmacol 35:467-472.
33. Wade LT, Kenna JG, and Caldwell J (1997) Immunochemical identification of mouse hepatic protein adducts derived from the nonsteroidal anti-inflammatory drugs diclofenac, sulindac, and ibuprofen. Chem Res Toxicol 10:546-555.
34. Walker AM (1997) Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs. Arthritis Rheum 40:201-208.
35. Zeng H, Liu G, Rea PA, and Kruh GD (2000) Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res 60:4779-4784.